Related Experiment Video
Updated: May 29, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
A 7-year-old with pulmonary hypertension.
James Olin1, Steven Abman, R Grady
1Department of Pediatrics, University of Colorado, Aurora, Colorado, USA.
Pulmonary capillary haemangiomatosis (PCH) is a rare cause of pulmonary hypertension. This case highlights PCH diagnosis and treatment challenges in a pediatric patient.
Area of Science:
- Cardiology
- Pulmonology
- Pathology
Background:
- Pulmonary arterial hypertension (PAH) can stem from various causes, including rare vascular pathologies.
- Pulmonary capillary haemangiomatosis (PCH) is an uncommon condition leading to severe pulmonary hypertension, often diagnosed late.
Purpose of the Study:
- To present a pediatric case of pulmonary capillary haemangiomatosis (PCH).
- To discuss diagnostic challenges and treatment strategies for PCH.
- To highlight the clinical course and outcome of PCH.
Main Methods:
- Case report of a 7-year-old female with exertional cyanosis and pulmonary hypertension.
- Diagnostic evaluation including assessment of cardiac function, response to vasodilators, and lung biopsy.
- Treatment with interferon α-2a and doxycycline for antiangiogenic effects.
Main Results:
- The patient presented with pulmonary hypertension and pulmonary edema, suggesting vascular pathology.
- Lung biopsy confirmed pulmonary capillary haemangiomatosis (PCH).
- Initial improvement with antiangiogenic therapy was followed by disease progression and fatality.
Conclusions:
- Pulmonary capillary haemangiomatosis (PCH) is a rare but critical diagnosis in pediatric pulmonary hypertension.
- Diagnosis often requires lung biopsy and can be challenging.
- While antiangiogenic therapies show potential, PCH remains a severe condition with a poor prognosis.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Other Pulmonary Disorders
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
